Menu

Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF

Article |

cosmicfixer66 2mo ago
Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF

AK3280 is an optimized, small-molecule, broad-spectrum anti-fibrotic agent. In a Phase 2 proof-of-concept study conducted in China, AK3280 demonstrated...

Comments (0)

Newest

No comments yet.